(Q38609568)

English

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders

scientific article published on 15 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

0 references

Kumar Visvanathan

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Benjamin C. Cowie

12

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Michelle L. Giles

object named as

Michelle Giles

3

0 references

author name string

Geoff Dusheiko

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

May-Ling Wong

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Nghi Phung

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Susan Walker

6

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Suong Le

7

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Seng Gee Lim

8

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Ed Gane

9

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Meng Ngu

10

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Winita Hardikar

11

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Scott Bowden

13

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Simone Strasser

14

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Miriam Levy

15

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Joe Sasaduesz

16

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

0 references

publication date

15 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

340-350

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Screening for hepatitis B virus infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Hepatitis B immunisation of household contacts: retrospective study of vaccine coverage

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Chronic hepatitis B infection in an Australian antenatal population: seroprevalence and opportunities for better outcomes.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Pregnancy and chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Hepatitis B in pregnancy: challenges and treatment

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

A Seroepidemiological Study of the Prevalence of Hepatitis B Infections in a Hyperendemic New Zealand Community

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: current standards of care

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Tenofovir rescue therapy in pregnant females with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Vertical transmission of hepatitis B virus despite maternal lamivudine therapy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Strategies to inhibit entry of HBV and HDV into hepatocytes.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Late preterm infants, early term infants, and timing of elective deliveries

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Interruption of HBV intrauterine transmission: a clinical study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Chronic hepatitis B virus (HBV) infection in children: 25 years' experience

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-310317

21 January 2018

Identifiers

10.1136/GUTJNL-2015-310317

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38609568&oldid=1770611469"